TARA
Protara TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TARA Profile
Protara Therapeutics, Inc.
A biopharmaceutical company that developing translational therapies for patients with rare and specific diseases
Biological Technology
03/24/2006
10/22/2014
NASDAQ Stock Exchange
28
12-31
Common stock
345 Park Avenue South, 3rd Floor, New York, NY 10010
--
Protara Therapeutics, Inc., was originally incorporated in Delaware on March 24, 2006. The company is a clinical-stage biopharmaceutical company based in New York City that advances transformative therapies for the treatment of cancer and rare diseases. The company's product portfolio includes two development projects utilizing TARA-002, an investigational cell therapy based on the broad immune-enhancing agent OK-432, which was originally granted marketing authorization by the Ministry of Health and Welfare of Japan as an immune-enhancing cancer treatment agent.
